2 recruiting. 1 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Recruiting 1 |
| Phase 3 | 1 | Recruiting 1 |
Follow Placebo - 100 mg: new trials by email Literature Review of Placebo - 100 mg trials Research Report on Placebo - 100 mg
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Learn About Ritlecitinib for the Potential Treatment of Chronic Spontaneous Urticaria in Adults. Ritlecitinib 50 mg, Ritlecitinib 100 mg, Placebo - 50 mg - Chronic Spontaneous Urticaria | Phase 2 | Recruiting | Pfizer | 200 | 2025-10-30 | 2026-06-17 |
| A Study of 2 Doses of Ritlecitinib in People 12 Years of Age and Older With Alopecia Areata Ritlecitinib 100 mg, Ritlecitinib 50 mg, Placebo - 100 mg - Alopecia Areata | Phase 3 | Recruiting | Pfizer | 674 | 2025-04-01 | 2026-10-20 |
Alopecia (1) · Alopecia Areata (1) · Alopecia universalis (1) · Chronic Urticaria (1) · Hair Diseases (1) · Pruritus (1) · Urticaria (1)
Pfizer (2)
Canada (2) · China (2) · Japan (2) · Poland (2) · South Korea (2) · Spain (2) · Taiwan (2) · United States (2) · Bulgaria (1) · Czechia (1) · Germany (1) · Puerto Rico (1) · United Kingdom (1)
2025 (1)